NASONEX ® is a drug based on Mometasone Furoate
THERAPEUTIC GROUP: Rhinologicals - Nasal decongestants and other preparations for topical use
Indications NASONEX ® Mometasone
NASONEX ® is indicated in the prevention and treatment of recurrent symptoms in seasonal or perennial allergic rhinitis of adults and pediatric patients.
Mechanism of action NASONEX ® Mometasone
Mometasone, the active ingredient of NASONEX ®, is a highly active corticosteroid commonly used in the clinical setting for its high efficacy of action at the topical-local level and the low systemic absorption which generally minimizes the risk of systemic adverse reactions.
Its biological activity, similar to those of all other corticosteroids, is basically carried out by inducing the expression of genes capable of counteracting the cascade of molecular events that leads to the formation of inflammatory mediators such as prostaglandins, leukotrienes and thromboxanes.
Scientific evidence has also shown that the anti-inflammatory action of Mometasone is added to the potentially anti-allergic action, observed by evaluating the reduced recruitment of eosinophils and neutrophils on site.
All this takes place both with the decongestion of the nasal mucosa, and therefore with the improvement of respiratory capacity, and with the reduction of the large symptomatological concentration that occurs during both seasonal and perennial allergic rhinitis.
Studies carried out and clinical efficacy
THE MOMETASONE IN NIGHT APNEA
Am J Rhinol Allergy. 2013 Jul-Aug; 27: e113-6. doi: 10.2500 / ajra.2013.27.3921.
The effects of mometasone furoate and desloratadine in obstructive sleep apnea syndrome patients with allergic rhinitis.
Acar M, Cingi C, Sakallioglu O, San T, Fatih Yimenicioglu M, Bal C.
Interesting study that demonstrates how treatment with Mometasone in patients suffering from allergic rhinitis can also significantly improve obstructive sleep apnea syndrome, resulting in a significant increase in the quality of life of these patients.
BRONCHODILATOR EFFECT OF MOMETASONE AND FORMOTEROL
Pediatr Pulmonol. 2013 Sep 9. doi: 10.1002 / ppul.22850. [Epub ahead of print]
Bronchodilation with mometasone furoate / formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma.
Berger WE, Bensch GW, Weinstein SF, Skoner DP, Prenner BM, Shekar T, Nolte H, Teper AA.
Work conducted on small patients aged between 5 and 11 years which demonstrates how the inhalation of Mometasone and Formoterol can guarantee a significant bronchodilation, such as to improve respiratory capacity.
COMPARING NASAL DECONGESTANTS
Allergy Asthma Proc. 2013 Sep 27. [Epub ahead of print]
A patient preference and satisfaction study of ciclesonide nasal aerosol and mometasone furoateaqueous nasal spray in patients with perennial allergic rhinitis.
Clinical trial that tests the preference of patients suffering from perennial allergic rhinitis towards local therapies based on Mometasone or Ciclesonide, preferring the latter for the more rapid and clear improvement of the complained symptoms.
Method of use and dosage
NASONEX ®
Nasal spray of 50 microgr of Mometasone furoate for dispensing.
Topical therapy with NASONEX ® should be established by the physician based on the patient's general health conditions and the severity of his clinical picture.
Generally, in the treatment of symptoms of allergic rhinitis in adults, 2 applications per nostril are recommended once a day in the initial phase, to halve the dosage in the subsequent maintenance phase.
The dosage envisaged for the treatment of symptoms in patients under 12 years of age and in the prophylaxis of nasal polyposis is different.
NASONEX ® Mometasone warnings
Given the presence of a corticosteroid as the active ingredient of NASONEX ®, medical supervision is recommended during the entire drug treatment.
For the same reason, patients with bacterial, viral, tuberculous or fungal infections should avoid the use of NASONEX ® due to the potential local immunosuppressive effects induced by the product, such as to aggravate the present clinical picture or significantly delay therapeutic resolution.
Prolonged use of NASONEX ®, also due to the presence of benzalkonium chloride as an excipient, could increase the risk of local adverse reactions of hypersensitivity.
Fortunately, systemic side effects related to the presence of Mometasone are rarer.
It is recommended to avoid prolonged use of the product and to contact your doctor immediately following the appearance of unwanted reactions.
PREGNANCY AND BREASTFEEDING
NASONEX ® is contraindicated during pregnancy and in the subsequent period of breastfeeding, given the absence of studies capable of fully characterizing the safety profile of Mometasone for the health of the fetus and infant.
Interactions
The very low systemic absorption that the Mometasone present in NASONEX ® undergoes, significantly reduces the risk of clinically relevant drug interactions.
Contraindications NASONEX ® Mometasone
The use of NASONEX ® is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, in patients with local infections and in patients undergoing surgery.
Undesirable Effects - Side Effects
The use of NASONEX ®, especially when prolonged for a long time, could cause the appearance of local adverse reactions such as: respiratory tract infections, epistaxis, headache, pharyngitis, nasal burning and nasal ulcerations.
Fortunately, systemic side effects of clinical note are rarer.
Note
NASONEX ® is a drug subject to mandatory medical prescription
The information on NASONEX ® Mometasone published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
